Scott Dodson

Scott has 30 years in the medical device space leading blue-chip organizations, mid-cap growth companies and venture backed firms up through successful IPO’s and exits. He thrives in the fast paced, ever changing market of medical technology and company consolidation and has established and grown businesses in every region of the world.

​By developing strong management teams, he has succeeded in bringing in and developing functional competency to the organizations that he has led while focusing the companies on creating the vision that they and their teams can help create, get behind and execute against. Throughout his career, Scott has been attracted to technology that makes a difference in the marketplace and can be combined with other technologies to form a portfolio that creates real value in highly differentiated market segments.

​In his most recent assignment at Holson Consulting, which he helped found, Scott has partnered with Correlation Ventures to leverage his vast experience in identifying medical device companies that are targets for incremental investments from the private equity community. Additionally, Scott assists established companies to identify new ‘revenue ready ‘technologies and opportunities to complement their existing organic portfolios. This effort has resulted in multiple acquisitions, partnerships and licensing agreements.

​Prior to this, Scott led AirXpanders, Inc., a device company that designs, manufactures and distributes a technology for breast cancer reconstruction as their President, CEO and Board Member. During his tenure, AirXpanders secured their regulatory approval for Europe, Australia and the United States while completing the largest randomized trial for implanted devices in the plastic surgery sector which helped to secure a de novo approval in the United States and bipartisan support on Capitol Hill for the Breast Cancer Patient Education Act.

​Scott led the company through an oversubscribed IPO process and converted the business to a publicly traded entity on the ASX in June, 2015 where the business quickly gained traction and secured a 30% market share within the first six months of commercialization. Scott also simultaneously scaled sales organizations in the United States and Australia while securing distribution partners throughout Europe. Overall, Scott raised over $40M in the PE market and over $70M in institutional funding in the US, Asia and Australia while transferring manufacturing to Costa Rica to achieve a 75% reduction in COGs.

​Before AirXpanders, Scott led Avanits Medical, a medical device company in the GI Medicine space as their President, CEO and Board Member. During his tenure, Avantis secured two FDA approvals, reimbursement through CMS and a successful manufacturing transfer for an 80% reduction in COGs. Scott raised more than $40M in private equity funding for Avantis in arguably the most difficult market environment in 2009 / 2010.

​Prior to AirXpanders, Scott led the Orthopedic Business Segment of Orthofix Intl. as their Global Business Unit President. With manufacturing locations in Dallas, TX and Verona, Italy, The Orthopedic GBU grew at 300% over the industry average at a 30% CAGR with a focused effort around consolidation and a unifying vision around functional competency and accountability throughout the organization.

Scott began his medical device career at The Boston Scientific Corporation where he spent 14 years in roles of increasing responsibility in the different business segments of Urology, Women’s Health, Gastroenterology, Interventional Radiology and International. While at Boston, Scott led teams in Sales, Marketing, Operations, Business Development, Commercialization, R&D and Communications as the company grew from a privately held $30M medical start-up to a multi-billion-dollar global player in the medical device sector.

Prior to Boston Scientific, Scott began his career with the Black and Decker Corporation in sales and sales management within the Industrial Construction segment which initiated the DeWalt Division.